LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Momentum-inputs (vergelijkbare managers):
breedte van houders +9.1% ·
aandelenstroom -2.3% ·
netto nieuwe posities +8.3%
— formule
Versnippering van eigendom — meer houders, kleinere totale positie
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 20.93M | +1.4% | $18.54B | 2.1% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.93M | +1.4% | $18.54B | 2.1% | ▲ Add | 2 | SEC ↗ |
| 3 | Capital World Investors ✦ | 20.36M | -6.7% | $18.03B | 2.8% | ▼ Trim | 2 | SEC ↗ |
| 4 | PRIMECAP Management ✦ | 17.69M | -9.8% | $15.67B | 11.5% | ▼ Trim | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passief) | 17.09M | +0.5% | $15.09B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passief) | 17.09M | +0.5% | $15.09B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 13 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 14 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 15 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 16 | Norges Bank ✦ (passief) | 10.49M | -4.7% | $9.29B | 1.3% | ▼ Trim | 2 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 5.06M | +3.5% | $4.48B | 1.8% | ▲ Add | 2 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 1.63M | +1.3% | $1.44B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 19 | Millennium Management ✦ | 990.21K | +86.1% | $877.27M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 20 | Tiger Global Management ✦ | 969.80K | +4.3% | $859.18M | 3.7% | ▲ Add | 2 | SEC ↗ |
| 21 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 22 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 23 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 24 | Adage Capital Partners ✦ | 829.38K | +0.2% | $734.78M | 1.3% | ▲ Add | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 30 | D. E. Shaw & Co. ✦ | 408.08K | +72.0% | $361.54M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 31 | D. E. Shaw & Co. ✦ | 408.08K | +72.0% | $361.54M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 32 | Renaissance Technologies ✦ | 257.81K | Nieuw | $228.41M | 0.3% | New | 1 | SEC ↗ |
| 33 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 34 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 35 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 36 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 37 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 38 | Citadel Advisors ✦ | 215.18K | -57.0% | $190.64M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 39 | Citadel Advisors ✦ | 215.18K | -57.0% | $190.64M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 40 | Two Sigma Investments ✦ | 199.74K | -11.5% | $176.95M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 41 | Viking Global Investors ✦ | 152.04K | +5.5% | $134.70M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 42 | Bridgewater Associates ✦ | 73.27K | -23.5% | $64.91M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 43 | Dodge & Cox ✦ | 45.09K | -1.9% | $39.95M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 44 | GAMCO Investors ✦ | 34.81K | -2.8% | $30.84M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 45 | Point72 Asset Management ✦ | 13.16K | Nieuw | $11.66M | 0.0% | New | 1 | SEC ↗ |
| 46 | Gotham Asset Management ✦ | 8.52K | -28.7% | $7.54M | 0.1% | ▼ Trim | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Renaissance Technologies | $228.41M | 0.3% |
| Point72 Asset Management | $11.66M | 0.0% |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 4,323 houders, 762.84M aandelen, $674.93B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 6.50K aand · $7.64M
Officer · 2.00K aand · $2.37M
Officer · 5.00K aand · $5.95M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters